• Biology, Medicine
  • Published in Journal of immunology 1996

A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis.

@article{Marini1996ACP,
  title={A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis.},
  author={Joseph C. Marini and B. A. Jameson and Fred D. Lublin and Robert Korngold},
  journal={Journal of immunology},
  year={1996},
  volume={157 8},
  pages={
          3706-15
        }
}
A structure-based design approach was used to develop a cyclized peptide analog of the murine CD4-CDR3-like region as a potential inhibitor of autoimmune CD4+ T cells responsible for the pathogenesis of experimental allergic encephalomyelitis (EAE). Our results indicate that this peptide, referred to as rD-mPGPtide, is able to significantly inhibit the clinical and pathologic symptoms of EAE in the SJL mouse model when administered on day 12 of induction. The optimum effective dosage range for… CONTINUE READING